Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company... see more

Recent & Breaking News (NDAQ:AMLX)

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Business Wire November 7, 2024

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Business Wire November 4, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Business Wire October 17, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Business Wire October 15, 2024

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

PR Newswire October 3, 2024

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Business Wire August 28, 2024

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Business Wire August 12, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Business Wire August 8, 2024

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Business Wire August 5, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Business Wire August 2, 2024

Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Sunnova Energy International Inc. (NYSE: NOVA), EQUINIX, INC. (NASDAQ: EQIX), and Altimmune, Inc. (NASDAQ: ALT)

Accesswire July 23, 2024

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

PR Newswire July 18, 2024

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Business Wire July 10, 2024

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Business Wire July 9, 2024

Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), bluebird bio, inc. (NASDAQ:BLUE), Nextdoor Holdings, Inc. (NYSE:KIND), and Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Accesswire July 2, 2024

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Newsfile July 2, 2024

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 4, 2024

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire May 31, 2024

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Business Wire May 9, 2024

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Business Wire May 8, 2024